MolecularMatch and Liquid Biotech USA Partner on Cancer Diagnostics

NEW YORK (GenomeWeb) – MolecularMatch and Liquid Biotech USA plan to partner to develop liquid biopsy technology for cancer, the companies said today.

As part of the partnership, Liquid Biotech, which is developing proprietary circulating tumor cell detection technology, will use MolecularMatch's database to correlate genomic test results with treatments. MolecularMatch, which was founded in 2014, has developed software to match the genetic profile of cancer patients' tumors to clinical trials and available drugs.

MoelcularMatch CEO Kevin Coker said in a statement that the partnership would help bridge the gap between liquid biopsy testing and the "resource-consuming matter of tracking innumerable treatments and trial data."

Liquid Biotech Chairman and CEO Phillip Sass added in the statement that the main advantage of his firm's test is in "early, precision detection," and that MolecularMatch's technology would complement its test by matching the results to available treatment and clinical trials, adding speed.

Liquid Biotech spun out of the University of Pennsylvania and raised $2 million last December to further develop its proprietary circulating tumor cell identification and isolation technology.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.

Sponsored by

This webinar will discuss how Sanofi used literature mining to annotate the association of human leukocyte antigen (HLA) alleles with diseases and drug hypersensitivity as part of a multiple sclerosis (MS) biomarker discovery project.

Sponsored by
Philips Genomics

This webinar will highlight a comprehensive end-to-end solution for precision care in oncology, comprising sample acquisition through to sequencing and analysis, treatment recommendations, and follow-through.

Sponsored by
Sophia Genetics

This webinar will discuss an effort underway at the University of North Carolina Medical Center's to overcome limitations in the hematological genomic testing workflow with artificial intelligence (AI) from Sophia Genetics.

Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.